piotr-adamowicz-shutterstock-com-gavel-
Piotr Adamowicz / Shutterstock.com
14 June 2016Americas

AstraZeneca asks FDA to delay ANDAs for Crestor generics

AstraZeneca has filed a citizen petition to the US Food and Drug Administration (FDA) requesting it to wait until 2023 before approving generic versions of Crestor (rosuvastatin calcium), a cholesterol treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 December 2020   A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

More on this story

Americas
22 December 2020   A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

More on this story

Americas
22 December 2020   A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.